Genomeditech(Shanghai) Co.LTD

EN

Insights

Resources

Current Position：Activity > News > Insights

Insights

GLP-1：Amgen’s MariTide Demonstrates 20% Weight Loss

IL-23：Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra

PD-1/VEGF BsAb : MSD Enters into Exclusive Global License for LM-299 from LaNova Medicines Ltd.

HER2: FDA Approves Application for Phase I Clinical Trial of Paragon HER2 ADC for Solid Tumours

AstraZeneca Announces Data from First-in-Human Phase 1 Study of AZD0486, a Novel CD19xCD3 T-Cell Activator, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

GLP-1R/GCGR/GIPR: Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis

BTK：Sanofi Announces Positive Data from Phase III Study of BTK Inhibitor ITP

CD19/CD20/CD3：GSK enters agreement to acquire CMG1A46 from Chimagen Bioscience

PD-1/VEGF：GlycoMimetics enters into acquisition agreement with Crescent biopharma

IL-17: UCB presents new 4-year data for BIMZELX[®](bimekizumab) in moderate to severe plaque psoriasis at EADV 2024

First Prev 3 4 5 6 7 Next Last

Total 7 Page

Jump

Current position：Activity > News > Insights

Classification

Insights

GLP-1：Amgen’s MariTide Demonstrates 20% Weight Loss

IL-23：Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra

PD-1/VEGF BsAb : MSD Enters into Exclusive Global License for LM-299 from LaNova Medicines Ltd.

HER2: FDA Approves Application for Phase I Clinical Trial of Paragon HER2 ADC for Solid Tumours

AstraZeneca Announces Data from First-in-Human Phase 1 Study of AZD0486, a Novel CD19xCD3 T-Cell Activator, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

GLP-1R/GCGR/GIPR: Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis

BTK：Sanofi Announces Positive Data from Phase III Study of BTK Inhibitor ITP

CD19/CD20/CD3：GSK enters agreement to acquire CMG1A46 from Chimagen Bioscience

PD-1/VEGF：GlycoMimetics enters into acquisition agreement with Crescent biopharma

IL-17: UCB presents new 4-year data for BIMZELX[®](bimekizumab) in moderate to severe plaque psoriasis at EADV 2024

MORE

Message consultation

                    
Toll-free hotline：400-627-9288
                    
Email address：mkt.genomeditech@gmail.com

Company address：5th Floor, Building 1, Lane 299, Kangwei Road, Pudong New District, Shanghai

Copyright © 2023 吉满生物科技（上海）有限公司 All rights reserved.

Message

Message consultation